161891-49-2

Upstream product

• 100-46-9 benzylamine 
• 53640-96-3 diethyl N-benzylphosphoramidate 
• 814-49-3 diethyl chlorophosphate 

Downstream Products

• 55595-96-5 diethyl <1-(diethoxyphosphinyl)-1-phenylmethyl>phosphoramidate 

Relevant academic research and scientific papers

METAL COMPLEX COMPOUND, CANCER THERAPEUTIC COMPOSITION COMPRISING THE METAL COMPLEX COMPOUND AS ACTIVE INGREDIENT, AND INTERMEDIATE FOR PRODUCTION OF THE METAL COMPLEX COMPOUND

A metal complex compound which exhibits a high degree of adsorption to bone or inhibition of cell growth, and is highly effective for therapy of a cancer metastasized to bone and therapy of the primary carcinoma thereof; a therapeutic agent composition for a cancer containing as an active ingredient the metal complex compound or a physiologically acceptable salt thereof; and an intermediate for the metal complex compound are provided. More concretely, a metal complex compound represented by the following General Formula (1): (wherein R1 independently represents C1-C10 alkyl which may be branched or have a substituent; or a C3-C30 cyclic group which may have a substituent; and X represents CHR2, an oxygen atom or NR5); a therapeutic agent composition for a cancer containing it as an active ingredient; and an intermediate for the metal complex compound are provided.

Transformation of Arylmethylamines into α-Aminophosphonic Acids via Metalated Phosphoramidates: Rearrangement of Partly Configurationally Stable N-Phosphorylated α-Aminocarbanions

N-Benzyl phosphoramidate was protected at nitrogen with a TMS, p-toluenesulfonyl, Boc, lithium carboxylate, or diethoxyphosphinyl group and metalated with s-BuLi or LDA at -78 °C at the benzylic carbon. For the latter three protecting groups, the intermediate α-amino(phenylmethyl)-lithiums isomerized to N-protected α-aminophosphonates (phosphoramidate-aminophosphonate rearrangement). (R)-N-[1-2H1]Phenylmethyl phosphoramidate in combination with Boc or (EtO)2P-(O) was used to demonstrate that metalation occurs with a high primary kinetic isotope effect (kH/kD 13-50) and migration of the diethoxyphosphinyl group with retention of configuration at carbon. Furthermore, the short-lived carbanion lithium pairs are partly configurationally stable as the aminophosphonates formed with the two protecting groups have enantiomeric excesses of 79 and 24%, respectively. When homochiral lithium amides derived from (R)-N-isopropyl-1-phenylethylamine and (R,R)-N,N-di(1-phenylethyl)amine were used to induce a phosphoramidate-aminophosphonate rearrangement, chiral nonracemic α-aminophosphonates were formed (ee 26-35%). Three racemic aminophosphonates were deprotected with hot 6 M HCl and purified by ion-exchange chromatography on Dowex 50W,H+ to exemplify the transformation of phenyl-, p-tolyl-, and (1′-naphthyl)methylamine into aminophosphonic acids via lithiated phosphoramidates.

SYNTHESE VON NEUEN IMIDOBISPHOSPHORSAEUREN

Bisphosphonates (P-C-P) are suitable for the treatment of bone disease, as for example osteoporosis.Bisphosphonates though have the disadvantage of possible accumulation in the bone.Therefore a synthesis for the imidobisphosphoric acids and salts (P-N-P)